Trial Halted for Bleeding Reduction With Abelacimab in AF
The phase 2 AZALEA-TIMI 71 trial in AF shows "an overwhelming reduction" in major and clinically relevant nonmajor bleeding with investigational Factor XI inhibitor abelacimab vs rivaroxaban.
Source: medscape.com